Aripiprazole: Clinical Trials

363 trials of Aripiprazole, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

257 completed, 40 terminated, 36 unknown, 11 withdrawn. 132 Phase 4, 109 Phase 3, 40 Phase 2, 39 Not applicable, 33 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 4132Completed 87, Unknown 20, Terminated 16, Withdrawn 4, Active not recruiting 2, Recruiting 2, Not yet recruiting 1
Phase 3109Completed 88, Terminated 13, Withdrawn 3, Recruiting 2, Unknown 2, Not yet recruiting 1
Phase 240Completed 27, Not yet recruiting 4, Terminated 3, Recruiting 2, Unknown 2, Withdrawn 2
Not applicable39Completed 17, Terminated 8, Unknown 8, Withdrawn 3, Active not recruiting 1, Not yet recruiting 1, Recruiting 1
Phase 133Completed 29, Recruiting 2, Unknown 2
Early Phase 11Unknown 1

Follow Aripiprazole: new trials by email Literature Review of Aripiprazole trials Research Report on Aripiprazole

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Post-acute Infectious Syndrome - Aripiprazole Symptom Evaluation (PAIS-AriSE)
Aripiprazole (low-dose, 1mg), Placebo - Post-acute Infectious Syndrome (PAIS), Post-COVID-19 Condition (PCC or Long COVID)
Phase 2Not yet recruitingChristiana Franke1382026-10-012026-07-20
The BAARD Study : Evaluating a Computerized Approach to Treatment Selection in Older Adults With Treatment Resistant Depression.
Aripiprazole Augmentation, Bupropion Augmentation - Late Life Treatment Resistant Depression, Depression - Major Depressive Disorder
Phase 2Not yet recruitingWashington University School of Medicine3002026-10-012026-10-16
Evaluating Safety and Efficacy of VV119 in Acute Schizophrenia Adults
VV119 2mg, VV119 4mg, VV119 6mg - Schizophrenia
Phase 2Not yet recruitingVigonvita Life Sciences5002026-07-312026-07-15
Aripiprazole in Body Focused Repetitive Behaviors
Placebo, Aripiprazole - Trichotillomania (Hair-Pulling Disorder), Dermatillomania
Phase 2Not yet recruitingUniversity of Chicago1002026-06-012025-10-02
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
Roluperidone, risperidone, aripiprazole - Negative Symptoms of Schizophrenia
Phase 3RecruitingMinerva Neurosciences3802026-04-232026-07-28
Steady-state Bioequivalence Study of Aripiprazole for Injection in Patients With Schizophrenia.
Aripiprazole for Injection - Schizophrenia
Not applicableNot yet recruitingCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.1162026-04-052026-04-23
Cerebellum-based Imaging Neural Markers for Antipsychotic Response
risperidone, aripiprazole - Psychosis; Acute
Phase 4RecruitingNorthwell Health1202025-11-012026-05-26
Quality of Life, Safety and Compliance of Patients Using Monotherapy or Combinatorial Therapy With Quetiapine for Treatment of Schizophrenia or Bipolar Affective Disorder
Quetiapine (drug), quetiapine + aripiprazole, quetiapine + haloperidol - Schizophrenia, Bipolar Affective Disorder
RecruitingBosnalijek D.D5002025-10-302026-10-15
Dopamine and Sensorimotor Function in Stuttering
Aripiprazole 10 MG, Placebo - Stuttering, Adult
Phase 1RecruitingUniversity of California, San Francisco252025-09-302026-08-19
Switching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression(SMART-I)
Sertraline, Agomelatine, Aripiprazole - Major Depressive Disorder (MDD)
Phase 4Not yet recruitingXinyu Zhou4002025-06-202025-06-10
Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR.
Group A: (Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol,anxiolytics: clonazepam, stedon, tavor antidepressants: seropram),, Group B (Pharmacotherapy and TAU) (Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol, clonazepam, stedon, tavor, antidepressants,, Group C (Pharmacotherapy and Psychotherapy) Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol, clonazepam, stedon, tavor, lithium, depakine - Treatment Resistant Schizophrenia, Treatment Resistant Bipolar Disorder
Phase 4Active not recruitingDr. Stavroula Rakitzi842025-06-042026-05-01
Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole
Escitalopram, Aripiprazole 5mg - Major Depressive Disorder (MDD), Rumination
Not applicableActive not recruitingCentral South University1082025-05-082026-06-12
A Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in Patients with Acute Schizophrenia
Hydrochloride Carliprazine capsules, Aripiprazole tablets - Acute Schizophrenia
Phase 3Not yet recruitingChengdu Kanghong Pharmaceutical Group Co., Ltd.3762024-10-012024-09-19
Sequential Multiple Assignment Randomized Trial for Bipolar Depression
Cariprazine, Aripiprazole/Escitalopram combination, Quetiapine - Bipolar I Disorder, Depression
Phase 4Active not recruitingMassachusetts General Hospital27262024-10-012025-12-16
Biomarkers to Enhance Early Schizophrenia Treatment
aripiprazole, risperidone, clozapine - Schizophenia Disorder
Phase 4RecruitingNorthwell Health1802024-09-042026-07-31
Magnetic Seizure Therapy for Psychotic Disorders
Magnetic seizure therapy by Magnetic stimulator, Antipsychotic medications (such as olanzpine, risperidone, aripiprazole, quetiapine, amisulpride, etc) - Psychotic Disorders
Not applicableRecruitingShanghai Jiao Tong University School of Medicine502024-09-012025-11-25
Maintenance Electroconvulsive Therapy (ECT) Versus Aripiprazole in Clozapine-resistant Schizophrenia
maintenance ECT, Aripiprazole tablet - Clozapine Resistant Schizophrenia
Phase 4UnknownAll India Institute of Medical Sciences, Bhubaneswar402024-08-102024-07-16
Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.
Lumateperone 42 mg, Risperidone 2 mg - Apathy, Schizophrenia
Phase 3RecruitingLouisiana State University Health Sciences Center Shreveport802024-06-012024-07-01
A Study Assessing the Efficacy and Safety of HS-10380 in Hospitalized Adults With Acute Schizophrenia
HS-10380 Low Dose, HS-10380 Medium dose, HS-10380 High Dose - SCHIZOPHRENIA 1 (Disorder)
Phase 2CompletedJiangsu Hansoh Pharmaceutical Co., Ltd.3632024-05-232026-04-24
Atypical Antipsychotic-induced Mitochondrial Dysfunction in Patients With Schizophrenia
Aripiprazole, Risperidone - Schizophrenia
Phase 4CompletedAll India Institute of Medical Sciences, Bhubaneswar602024-04-052025-11-25

Showing 20 of 363. Sign in to see all of them.

Conditions studied

Schizophrenia (163)  ·  Psychotic Disorders (59)  ·  Bipolar Disorder (44)  ·  Depressive Disorder, Major (33)  ·  Depression (20)  ·  Autistic Disorder (14)  ·  Metabolic Syndrome (12)  ·  Tourette Syndrome (10)  ·  Mental Disorders (8)  ·  Tic Disorders (8)  ·  Depressive Disorder, Treatment-Resistant (7)  ·  Diabetes Mellitus (7)  ·  Alcoholism (6)  ·  Alzheimer Disease (6)  ·  Attention Deficit Disorder with Hyperactivity (6)

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc. (85)  ·  Otsuka Pharmaceutical Co., Ltd. (13)  ·  Massachusetts General Hospital (8)  ·  Northwell Health (8)  ·  Otsuka Beijing Research Institute (7)  ·  Fundación Marques de Valdecilla (6)  ·  Indiana University (5)  ·  Janssen Research & Development, LLC (5)  ·  Korea Otsuka Pharmaceutical Co., Ltd. (5)  ·  Washington University School of Medicine (5)  ·  All India Institute of Medical Sciences, Bhubaneswar (4)  ·  Bristol-Myers Squibb (4)  ·  Denovo Biopharma LLC (4)  ·  Medical University of South Carolina (4)  ·  New York State Psychiatric Institute (4)

Countries

United States (194)  ·  China (31)  ·  South Korea (29)  ·  Canada (27)  ·  Taiwan (26)  ·  Spain (24)  ·  Hungary (20)  ·  Germany (19)  ·  Romania (18)  ·  France (17)  ·  Russia (17)  ·  Bulgaria (16)  ·  India (16)  ·  Japan (15)  ·  Croatia (13)

Top investigators

Eva Kohegyi, MD (7)  ·  Katsuhisa Saito (7)  ·  Benedicto Crespo-Facorro, Professor (6)  ·  Linmarie Sikich, MD (4)  ·  Kyoji Imaoka, Mr (3)  ·  Patyman Juma (3)  ·  Robert L Findling, MD (3)  ·  Eric Lenze, MD (2)  ·  Ginger Nicol, MD (2)

Results publications

PMID 37811711, PMID 18832427, PMID 21731833, PMID 23106023, PMID 23585997, PMID 23585999, PMID 24766999, PMID 38958149, PMID 20816039, PMID 21731831, PMID 22697189, PMID 24138011, PMID 24925984, PMID 25711509, PMID 26232241, PMID 28204607, PMID 29856773, PMID 30097769, PMID 30420252, PMID 37756123, PMID 38085556, PMID 41034820, PMID 42138587, PMID 10686270, PMID 11691689, PMID 1308374, PMID 14661862, PMID 15685125, PMID 15800181, PMID 16801664, PMID 17074942, PMID 17229469, PMID 17284127, PMID 17284138, PMID 17287825, PMID 17502776, PMID 17592907, PMID 17620483, PMID 17805214, PMID 17909124, PMID 17960961, PMID 18204334, PMID 18312036, PMID 18370574, PMID 18373615, PMID 18425072, PMID 18605811, PMID 18626272, PMID 18759644, PMID 18765484

NIH funding

2009 (5), P50AA010761 (2), 1UG3MH137353-01 (1), 2017 (1), 2018 (1), K23MH081285 (1), N01MH090001 (1), N01MH90001 (1), P30MH071478 (1), R01DA020429 (1), R01DA022190 (1), R01DA023387 (1), R01MH059312 (1), R01MH060004 (1), R01MH071536 (1)